Literature DB >> 23340297

PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction.

Kaoru Abiko1, Masaki Mandai, Junzo Hamanishi, Yumiko Yoshioka, Noriomi Matsumura, Tsukasa Baba, Ken Yamaguchi, Ryusuke Murakami, Ayaka Yamamoto, Budiman Kharma, Kenzo Kosaka, Ikuo Konishi.   

Abstract

PURPOSE: Ovarian cancer often progresses by disseminating to the peritoneal cavity, but how the tumor cells evade host immunity during this process is poorly understood. Programmed cell death 1 ligand 1 (PD-L1) is known to suppress immune system and to be expressed in cancer cells. The purpose of this study is to elucidate the function of PD-L1 in peritoneal dissemination. EXPERIMENTAL
DESIGN: Ovarian cancer cases were studied by microarray and immunohistochemistry. PD-L1 expression in mouse ovarian cancer cell line in various conditions was assessed by flow cytometry. PD-L1-overexpression cell line and PD-L1-depleted cell line were generated, and cytolysis by CTLs was analyzed, and alterations in CTLs were studied by means of timelapse and microarray. These cell lines were injected intraperitoneally to syngeneic immunocompetent mice.
RESULTS: Microarray and immunohistochemistry in human ovarian cancer revealed significant correlation between PD-L1 expression and peritoneal positive cytology. PD-L1 expression in mouse ovarian cancer cells was induced upon encountering lymphocytes in the course of peritoneal spread in vivo and coculture with lymphocytes in vitro. Tumor cell lysis by CTLs was attenuated when PD-L1 was overexpressed and promoted when it was silenced. PD-L1 overexpression inhibited gathering and degranulation of CTLs. Gene expression profile of CTLs caused by PD-L1-overexpressing ovarian cancer was associated with CTLs exhaustion. In mouse models, PD-L1 depletion resulted in inhibited tumor growth in the peritoneal cavity and prolonged survival.
CONCLUSION: PD-L1 expression in tumor cell promotes peritoneal dissemination by repressing CTL function. PD-L1-targeted therapy is a promising strategy for preventing and treating peritoneal dissemination.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23340297     DOI: 10.1158/1078-0432.CCR-12-2199

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  77 in total

1.  Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy.

Authors:  Dongli Cai; Jiaming Li; Dingfeng Liu; Shanjuan Hong; Qin Qiao; Qinli Sun; Pingping Li; Nanan Lyu; Tiantian Sun; Shan Xie; Li Guo; Ling Ni; Liping Jin; Chen Dong
Journal:  Cell Mol Immunol       Date:  2019-10-14       Impact factor: 11.530

2.  Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma.

Authors:  Yuki Honda; Atsushi Otsuka; Sachiko Ono; Yosuke Yamamoto; Judith A Seidel; Satoshi Morita; Masahiro Hirata; Tatsuki R Kataoka; Tatsuya Takenouchi; Kazuyasu Fujii; Takuro Kanekura; Yuko Okubo; Kenzo Takahashi; Teruki Yanagi; Daichi Hoshina; Hiroo Hata; Riichiro Abe; Taku Fujimura; Takeru Funakoshi; Koji Yoshino; Mamiko Masuzawa; Yasuyuki Amoh; Ryota Tanaka; Yasuhiro Fujisawa; Tetsuya Honda; Kenji Kabashima
Journal:  Oncoimmunology       Date:  2016-11-04       Impact factor: 8.110

3.  Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model.

Authors:  Jyothi Thyagabhavan Mony; Lixin Zhang; Tianzhou Ma; Shannon Grabosch; Tejas S Tirodkar; Joan Brozick; George Tseng; Esther Elishaev; Robert P Edwards; Xin Huang; Anda M Vlad
Journal:  Cancer Immunol Immunother       Date:  2015-05-22       Impact factor: 6.968

4.  Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.

Authors:  Jun Zhou; Kathleen M Mahoney; Anita Giobbie-Hurder; Fengmin Zhao; Sandra Lee; Xiaoyun Liao; Scott Rodig; Jingjing Li; Xinqi Wu; Lisa H Butterfield; Matthias Piesche; Michael P Manos; Lauren M Eastman; Glenn Dranoff; Gordon J Freeman; F Stephen Hodi
Journal:  Cancer Immunol Res       Date:  2017-05-18       Impact factor: 11.151

Review 5.  PD-L1 in melanoma: facts and myths.

Authors:  Mario Mandalà; Barbara Merelli; Daniela Massi
Journal:  Melanoma Manag       Date:  2016-08-22

6.  Naive CD4+ T Cells Carrying a TLR2 Agonist Overcome TGF-β-Mediated Tumor Immune Evasion.

Authors:  Mohsen Ibrahim; Davide Scozzi; Kelsey A Toth; Donatella Ponti; Daniel Kreisel; Cecilia Menna; Elena De Falco; Antonio D'Andrilli; Erino A Rendina; Antonella Calogero; Alexander S Krupnick; Andrew E Gelman
Journal:  J Immunol       Date:  2017-12-06       Impact factor: 5.422

7.  Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway.

Authors:  Tao Yin; Guoping Wang; Sisi He; Guobo Shen; Chao Su; Yan Zhang; Xiawei Wei; Tinghong Ye; Ling Li; Shengyong Yang; Dan Li; Fuchun Guo; Zeming Mo; Yang Wan; Ping Ai; Xiaojuan Zhou; Yantong Liu; Yongsheng Wang; Yuquan Wei
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

8.  Autologous graft versus myeloma: it's not a myth.

Authors:  Shuai Dong; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

9.  BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

Authors:  Hengrui Zhu; Fee Bengsch; Nikolaos Svoronos; Melanie R Rutkowski; Benjamin G Bitler; Michael J Allegrezza; Yuhki Yokoyama; Andrew V Kossenkov; James E Bradner; Jose R Conejo-Garcia; Rugang Zhang
Journal:  Cell Rep       Date:  2016-09-13       Impact factor: 9.423

10.  The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27.

Authors:  Sènan M d'Almeida; Gilles Kauffenstein; Charlotte Roy; Laetitia Basset; Loukas Papargyris; Daniel Henrion; Véronique Catros; Norbert Ifrah; Philippe Descamps; Anne Croue; Pascale Jeannin; Marc Grégoire; Yves Delneste; Julie Tabiasco
Journal:  Oncoimmunology       Date:  2016-04-28       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.